| Bioactivity | GPi688 is a potent and orally active glycogen phosphorylase (GPa) inhibitor with IC50s of 19 nM, 61 nM and 12 nM for human liver GPa, rat liver GPa and human skeletal muscle GPa, respectively[1]. GPi688 can inhibit glucagons-mediated glucose output in rat primary hepatocytes. GPi688 can be used for researching glucagon-mediated hyperglycaemia[2]. |
| Target | IC50: 19 nM (human liver GPa), 61 nM (rat liver GPa), 12 nM (human skeletal muscle GPa) |
| Name | GPi688 |
| CAS | 918902-32-6 |
| Formula | C19H18ClN3O4S |
| Molar Mass | 419.88 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Freeman S, et al. Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation state of the enzyme. Br J Pharmacol. 2006;149(6):775-785. [2]. Poucher SM, et al. An assessment of the in vivo efficacy of the glycogen phosphorylase inhibitor GPi688 in rat models of hyperglycaemia. Br J Pharmacol. 2007;152(8):1239-1247. |
GPi688
CAS: 918902-32-6 F: C19H18ClN3O4S W: 419.88
GPi688 is a potent and orally active glycogen phosphorylase (GPa) inhibitor with IC50s of 19 nM, 61 nM and 12 nM for hum
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.